Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Cardeas raises $34M in series B

Infectious disease company Cardeas Pharma Corp. (Seattle, Wash.) raised

Read the full 99 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE